1603. Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide -the DYAD study

BACKGROUND: In TANGO, switching to dolutegravir/lamivudine (DTG/3TC) was noninferior compared to continuing a tenofovir alafenamide (TAF)-based regimen, however switching from bictegravir (BIC)/emtricitabine (F)/TAF was not evaluated. Here, we present efficacy and safety of switching to DTG/3TC comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Rolle, Charlotte-Paige M, Castano, Jamie, Nguyen, Vu, Hinestrosa, Federico, DeJesus, Edwin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679308/
http://dx.doi.org/10.1093/ofid/ofad500.1438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679308/
http://dx.doi.org/10.1093/ofid/ofad500.1438

Ejemplares similares